Cite

    Claus Bachert et al.. “A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity..” Clinical and translational allergy, vol. 5, no. 4, 2015, p. 1. http://access.bl.uk/ark:/81055/vdc_100080434925.0x000444